Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $80,000.00 income · posted Apr 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 4
Health Issues

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain.

Medicare/Medicaid

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

Trade (domestic/foreign)

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Pharmacy

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem